Summary of Arcturus Therapeutics Q4 2025 Earnings Call

1Key Financial Results and Metrics

Revenue: Year-over-year revenue decreased by $70.3 million annually and $15.6 million quarterly, primarily due to reduced activity in the CSL collaboration and fewer development milestones as the Costave vaccine was commercialized.

Expenses: Research and development expenses fell by $83.0 million annually and $19.3 million quarterly, attributed to lower manufacturing and clinical costs related to the LUNAR-COV19 program transitioning to commercial status. General and administrative expenses decreased by $6.7 million annually but increased by $1.6 million quarterly due to accelerated employee stock options.

Cash Position: As of December 31, 2025, cash, cash equivalents, and restricted cash totaled $232.8 million, down from $293.9 million a year prior. The company has extended its cash runway into Q2 2028.

2Strategic Updates and Business Highlights

Pipeline Progress:

ARCT-032 (Cystic Fibrosis): Phase II trial is set to begin in H1 2026, focusing on a 12-week study with 20 participants. The trial aims to evaluate safety and early clinical benefits, including lung function and quality of life metrics.

ARCT-810 (OTC Deficiency): Moving towards pivotal development with Type C regulatory meetings scheduled for H1 2026 to clarify the clinical strategy for both adult and pediatric populations.

Costave (COVID-19 Vaccine): Received approval from the U.K. Medicines and Healthcare Products Regulatory Agency for use in adults.

ARCT-2304 (Influenza Vaccine): Completed Phase I study showing durable immune response across all doses, reinforcing the STARR® sa-mRNA platform's efficacy.

3Forward Guidance and Outlook

The company anticipates generating meaningful clinical data from the ARCT-032 program in 2026 and is focused on achieving multiple near-term milestones in its therapeutic programs. The management expressed confidence in their financial position and the ability to fund ongoing clinical trials.

4Bad News, Challenges, or Points of Concern

Declining Revenue: The significant drop in revenue from collaborations raises concerns about the sustainability of income streams.

Regulatory Challenges: The ongoing discussions with regulatory authorities regarding the OTC program's pivotal trial design highlight potential hurdles in gaining approval.

Market Competition: The competitive landscape for both cystic fibrosis and OTC deficiency treatments remains a concern, particularly as companies vie for similar patient populations.

5Notable Q&A Insights

Study Design Optimizations: The upcoming 12-week CF study will include more stringent baseline stability criteria and additional quality of life measures to enhance the reliability of results.

Dosing Flexibility: There is a possibility to adjust dosing during the study based on ongoing data collection, with a focus on maintaining cost-effectiveness.

Regulatory Engagement: The company is actively preparing for Type C meetings with the FDA to clarify endpoints and study designs for the OTC program, indicating a proactive approach to regulatory challenges.

Patient Enrollment Strategy: The company is enhancing its patient recruitment strategy by expanding sites internationally, particularly in regions with a higher prevalence of specific CF mutations. Overall, while Arcturus Therapeutics is making progress in its clinical programs and maintaining a solid financial position, it faces challenges related to declining revenues and regulatory hurdles that could impact its future growth and development.